Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference
February 18 2014 - 8:00AM
Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R.
Edick, CEO, will present an overview of the Company at the 2014 RBC
Capital Markets' Global Healthcare Conference in New York on
Tuesday, February 25, 2014 at 11:30 am EST.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for
patients with infectious diseases and acute illnesses. Durata has
completed two global Phase 3 clinical trials with its lead product
candidate, dalbavancin, under investigation for the treatment of
patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.
Forward-looking statements
Any statements in this press release about Durata's future
expectations, plans and prospects constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will
cause its views to change. However, while Durata may elect to
update these forward-looking statements at some point in the
future, Durata specifically disclaims any obligation to do so.
CONTACT: Allison Wey
Durata Therapeutics, Inc.
Vice President, Investor Relations and Public Affairs
(312) 219-7017
awey@duratatherapeutics.com
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
(MM) (NASDAQ:DRTX)
Historical Stock Chart
From Oct 2023 to Oct 2024